Extending nature's leads: the anticancer agent ellipticine.
about
Sequence effect of self-assembling peptides on the complexation and in vitro delivery of the hydrophobic anticancer drug ellipticinePharmacokinetics of peptide mediated delivery of anticancer drug ellipticineAttenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppressionChemical Library Screening and Structure-Function Relationship Studies Identify Bisacodyl as a Potent and Selective Cytotoxic Agent Towards Quiescent Human Glioblastoma Tumor Stem-Like CellsMinigenome-based reporter system suitable for high-throughput screening of compounds able to inhibit Ebolavirus replication and/or transcription.DNA-Destabilizing Agents as an Alternative Approach for Targeting DNA: Mechanisms of Action and Cellular ConsequencesStudy of DNA-ellipticine interaction by capillary electrophoresis with laser-induced fluorescence detection.Formation of DNA adducts by ellipticine and its micellar form in rats - a comparative study.The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes.Ellipticine cytotoxicity to cancer cell lines - a comparative studyImmunomodulatory Response Triggered by the Alkaloids, 3-Amino-7-Benzylbenzimidazo[3,2-a] Quinolinium Chloride (ABQ-48) and 3-Nitro-7-Benzylbenzimidazo [3,2-a] Quinolinium Chloride (NBQ-48)Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo.Synthesis and biological activity of 5-aza-ellipticine derivativesOld drug, new target: ellipticines selectively inhibit RNA polymerase I transcription.Inhibition of human DNA topoisomerase IIα by two novel ellipticine derivatives.Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73Molecular recognition of poly(A) by small ligands: an alternative method of analysis reveals nanomolar, cooperative and shape-selective binding.Natural products and their role in cancer therapy.Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy.7-formyl-10-methylisoellipticine, a novel ellipticine derivative, induces mitochondrial reactive oxygen species (ROS) and shows anti-leukaemic activity in mice.Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage.Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.Synthesis and antiproliferative activity of some ellipticine-like 11H-pyrido[a]carbazole derivatives.Synthesis and preliminary antiproliferative evaluation of 1,3,9-triazacyclopenta[b]fluorene derivatives.Identification of G-Quadruplex Inducers Usinga Simple, Inexpensiveand Rapid High Throughput Assay, and TheirInhibition of Human TelomeraseCytochrome b5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine.Correlating gene expression with chemical scaffolds of cytotoxic agents: ellipticines as substrates and inhibitors of MDR1.Stimulation of suicidal erythrocyte death by ellipticine.Towards natural mimetics of metformin and rapamycin.The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells.Nuclear quantum effects in a HIV/cancer inhibitor: The case of ellipticine.Preparation of pH-Responsive Polymer Core-Shell Nanospheres for Delivery of Hydrophobic Antineoplastic Drug Ellipticine
P2860
Q28472517-BACB91DA-2F55-4220-8232-535CB352EF87Q28483163-3396A037-6A99-4B77-9F14-4350E84B373CQ28486134-7F1A385C-5107-41D0-A8DD-98F54FE3AC0AQ28547244-7EB21B45-7892-4913-AB91-0FC7CF262ED8Q33962901-BC1DE38C-A8B3-4C6F-B0C4-348D9F8B4508Q34042848-7832194C-FC3B-4A2E-8D2E-9A8F87535C35Q34317934-1ED32E36-09CA-4FC8-976E-C58E6AB199F3Q34984928-4E5EB000-CACF-4FA8-B0C2-AB3012260415Q35016427-CB3B69FD-ECFD-478F-91A4-16EBDB91B04EQ35092039-12A0BBD9-4CB6-4EEB-815F-1A53988BD11AQ35743952-B55D8688-6C61-410D-9711-6CCB6BC76E46Q36093919-18E92F83-4149-47ED-88BB-EE9FAC2C1736Q36487813-831DC97D-5C71-43F6-8600-47F3F359CFA4Q36620686-58B04D1E-B832-4B14-9EF1-C830B771BE73Q36669680-E0B13167-8F1C-4654-9EFD-1FE14B42EAEDQ36766944-B4BE0E4A-32A0-425A-8847-A85B9D57F08EQ37077372-6647D75D-CD54-47D2-8501-7F550B9BD4C1Q37736333-6795FA07-1BB2-4B29-9F0E-F2F7F4B65B4BQ37818291-20A745CB-6781-4D2F-9E2C-13FE8EE1079BQ38820155-75C55F94-5937-4F85-8251-62179365B601Q38988248-2CDCB9D0-C07A-49D5-B097-E98C5855BF0BQ39211628-768568F3-D487-4A67-A005-E8F91C165ABEQ39492938-9EE7B66B-B1A6-4717-B4A6-1B13DEF42958Q40330720-6E4F28CB-A20C-4C77-BDB4-9002B3B2DB64Q41630512-E6B15BC4-5E37-43D0-9ECA-CA4CB1717DBAQ44457504-C9D27270-9839-47B8-9C22-E7A3CFCCE7E3Q45236964-BB50601E-CAF8-4C19-8615-10E5A79390C7Q46814531-C16A1AAC-2FF8-4AAE-9688-C9BA8103F52AQ47140599-A26F7E6E-1F28-49A4-9EA9-AF94E1B7D843Q48303460-84CDF2B7-6CF4-404A-BB01-DEAB62248203Q50193792-2CA246A8-065A-4520-AD98-FC51B34C6651Q57349010-E034D22C-110E-4F3A-BECD-D0D916709D1B
P2860
Extending nature's leads: the anticancer agent ellipticine.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Extending nature's leads: the anticancer agent ellipticine.
@ast
Extending nature's leads: the anticancer agent ellipticine.
@en
type
label
Extending nature's leads: the anticancer agent ellipticine.
@ast
Extending nature's leads: the anticancer agent ellipticine.
@en
prefLabel
Extending nature's leads: the anticancer agent ellipticine.
@ast
Extending nature's leads: the anticancer agent ellipticine.
@en
P356
P1476
Extending nature's leads: the anticancer agent ellipticine.
@en
P2093
David E Graves
Nichola C Garbett
P304
P356
10.2174/1568011043482070
P577
2004-03-01T00:00:00Z